Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter’s transformation
Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL
